Literature DB >> 8508365

The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.

H A Frazier1, J E Robertson, R K Dodge, D F Paulson.   

Abstract

BACKGROUND: A recent consensus conference on bladder carcinoma highlighted the need for pathologic predictors of outcome for patients with transitional cell carcinoma of the bladder. This review was undertaken to determine the pathologic features predictive of cancer-specific survival after a radical cystectomy and urinary diversion for transitional cell carcinoma of the bladder and prostate.
METHODS: Between 1969 and 1990, 531 patients with transitional cell carcinoma of the bladder and prostate were treated with radical cystectomy at the Duke University Medical Center. Records and pathologic specimens were analyzed and correlated with outcome. Both univariate and multivariate analyses of the pathologic staging were performed to identify variables predictive of cancer-specific survival.
RESULTS: Univariate analysis indicated that pathologic tumor (pT) stage, positive nodes, positive surgical margins, prostatic stromal involvement, grade, age, ureteral involvement, squamous cell carcinoma, and squamous cell differentiation in the specimen all were predictive of poor cancer-specific survival. Carcinoma in situ (CIS) in the specimen was not an adverse prognostic indicator. Multivariate analysis demonstrated that the pT stage, nodal involvement, positive surgical margins, patient's age at surgery, and loss of histologic differentiation were predictive of poor cancer-specific survival. CIS was found again not to have a negative influence on cancer-specific survival.
CONCLUSIONS: If any of these features are noted in the final pathologic specimen, patients should be considered for some form of additional postoperative treatment such as chemotherapy or radiation therapy in an attempt to improve their chances for cancer-free survival. These factors will become more important in selecting which patients should be placed in developing adjuvant clinical trials.

Entities:  

Mesh:

Year:  1993        PMID: 8508365     DOI: 10.1002/1097-0142(19930615)71:12<3993::aid-cncr2820711233>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

2.  Keratin 6 expression correlates to areas of squamous differentiation in multiple independent isolates of As(+3)-induced bladder cancer.

Authors:  Ling Cao; Xu Dong Zhou; Mary Ann Sens; Scott H Garrett; Yun Zheng; Jane R Dunlevy; Donald A Sens; Seema Somji
Journal:  J Appl Toxicol       Date:  2010-07       Impact factor: 3.446

3.  The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.

Authors:  Andrea Slusser-Nore; Scott H Garrett; Xu Dong Zhou; Donald A Sens; Mary Ann Sens; Seema Somji
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-10       Impact factor: 4.219

4.  Elevated connexin 43 expression in arsenite-and cadmium-transformed human bladder cancer cells, tumor transplants and selected high grade human bladder cancers.

Authors:  Ruowen Zhang; Liping Wang; Scott H Garrett; Donald A Sens; Jane R Dunlevy; Xu Dong Zhou; Seema Somji
Journal:  Exp Toxicol Pathol       Date:  2016-08-13

5.  Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis.

Authors:  Ali Canoğlu; Cağatay Göğüş; Yaşar Bedük; Diclehan Orhan; Ozden Tulunay; Sümer Baltaci
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.

Authors:  Behfar Ehdaie; Steven C Smith; Dan Theodorescu
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

7.  Surveillance strategies after definitive therapy of invasive bladder cancer.

Authors:  Ilias Cagiannos; Christopher Morash
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  Pattern of failure in bladder cancer patients treated with radical cystectomy: rationale for adjuvant radiotherapy.

Authors:  Yong Bae Kim; Sung Joon Hong; Seung Cheol Yang; Jae Ho Cho; Young Deuk Choi; Gwi Eon Kim; Koon Ho Rha; Woong Kyu Han; Nam Hoon Cho; Young Taek Oh
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

9.  Variation of keratin 7 expression and other phenotypic characteristics of independent isolates of cadmium transformed human urothelial cells (UROtsa).

Authors:  Seema Somji; Xu Dong Zhou; Aaron Mehus; Mary Ann Sens; Scott H Garrett; Krista L Lutz; Jane R Dunlevy; Yun Zheng; Donald A Sens
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

10.  [Prevalence of lymph node metastases in non-muscle-invasive bladder cancer. Delay of radical cystectomy and upstaging in the cystectomy specimen as risk factors].

Authors:  C Wiesner; C Thomas; A Salzer; R Gillitzer; C Hampel; J W Thüroff
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.